Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether the experimental vaccine G250 with or without IL-2 can produce an immune response in patients with renal cell carcinoma who have had all their cancer removed by surgery.


Clinical Trial Description

Renal cell carcinoma is a chemotherapy and radiotherapy resistant neoplasm that has a poor prognosis. Immunotherapy with the biologic agent IL-2 consistently produces a response rate of 10-15 %. Currently, for patients with locally advanced disease or patients with solitary metastases, the only treatment modality with a curative potential is surgical resection. There is presently no approved agent for use as adjuvant therapy after surgical resection to decrease the risk of recurrence. Peptide-based vaccine approaches offer an attractive treatment option.

The high prevalence of G250 in RCC, the definition of an HLA-A2-restricted epitope (the most common HLA type), and its immunogenicity makes it the most attractive candidate for peptide-based vaccine approaches in RCC therapy. The promising preclinical and clinical evidence provides the rationale for the use of IL-2 to potentiate the antitumor effects of cancer vaccines.

There is presently no conclusive data on the best dose of IL-2 to use as an adjuvant to cancer vaccines. One paradoxical finding in preclinical and clinical trials is that despite the enhancement in the antitumor effects of cancer vaccines, the number of antigen-specific CTL is not increased when IL-2 is given with a cancer vaccine 35]. In contrast, patients treated with peptide vaccines (without IL-2) in some melanoma trials had evidence of high levels of antigen-specific CTL, with no tumor regression observed 36]. Some possible explanations include capillary leak from high dose IL-2 resulting in CTL leaving the circulation and the possibility that high dose IL-2 decreases efficient T-cell priming. A more recent explanation has been proposed through advances in the mechanism of 1-cell activation. As their level of activation increases, T-cells become more susceptible to apoptosis. This phenomenon is known as activation-induced cell death (AICD) IL-2 may then have a role in the amplification and downregulation of the immune response. High dose IL-2 may help in augmenting the increase in the activation of CTL, but this may lead to increase their susceptibility to AJCD. The evidence in animal models that low doses of IL-2 were sufficient in increasing the potency of DC-based immunizations provides the rational for our study.

In our current study, the lowest dose of IL-2 (1 x 106 IU) is similar to the doses used by Yee et al. in their adoptive I cell therapy. This dose has been shown to expand and maintain CTLs in both preclinical and clinical models. The highest dose (11 x 106 IU) was chosen based on the expected toxicities from higher doses of IL-2 and our experience with this dose as a single agent in RCC.

Our hypothesis is that immunization with G250/Montanide/GM-CSF plus IL-2 can lead to an expansion of G250-specific CTL and result in killing of 0250 expressing micrometastatic RCC. We propose a dose finding study of escalating low doses of IL 2 (subcutaneous), since no prior study has specifically evaluated the use of low dose IL-2 as a cytokine adjuvant and attempted to establish a correlation between dose and immunolgic response. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00203866
Study type Interventional
Source University of Chicago
Contact
Status Terminated
Phase Phase 2
Start date October 2003
Completion date March 2007

See also
  Status Clinical Trial Phase
Completed NCT00930033 - Clinical Trial to Assess the Importance of Nephrectomy Phase 3
Recruiting NCT05863351 - Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study Phase 3
Completed NCT00414765 - Aldesleukin in Participants With Metastatic Renal Cell Carcinoma or Metastatic Melanoma Phase 4
Active, not recruiting NCT03149822 - Study of Pembrolizumab and Cabozantinib in Patients With Metastatic Renal Cell Carcinoma Phase 1/Phase 2
Recruiting NCT03647878 - Study of Cabozantinib as Monotherapy or in Combination With Nivolumab in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment.
Completed NCT01517243 - Phase II Study of Alternating Sunitinib and Temsirolimus Phase 2
Withdrawn NCT03927248 - PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer Phase 1/Phase 2
Terminated NCT02122003 - Second Line Sorafenib After Pazopanib in Patients With RCC Phase 2
Completed NCT01182142 - Study of Capecitabine in Metastatic Non-clear Cell Renal Cell Carcinoma (RCC) Patients Phase 2
Completed NCT00630409 - Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma Phase 2
Recruiting NCT04140526 - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC Phase 1/Phase 2
Completed NCT04076787 - Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Active, not recruiting NCT04467021 - Cancer and Blood Pressure Management, CARISMA Study N/A
Recruiting NCT05119335 - A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma Phase 1/Phase 2
Completed NCT02282579 - Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy
Terminated NCT02071641 - Phase II Study of Sunitinib Rechallenge in Patients With Metastatic Renal Cell Carcinoma Phase 2
Completed NCT01731158 - Sequential Therapy in Metastatic Renal Cell Carinoma Phase 2
Terminated NCT01342627 - Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma Phase 2
Active, not recruiting NCT01274273 - Study of Interleukin-2, Interferon-alpha and Bevacizumab in Metastatic Kidney Cancer Phase 2
Completed NCT00848640 - Study of Sorafenib in Patients With Advanced Renal Cell Carcinoma Phase 2